Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis.

Magrì A, Reina S, De Pinto V.

Front Chem. 2018 Apr 6;6:108. doi: 10.3389/fchem.2018.00108. eCollection 2018. Review.

2.

Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis.

Di B, Pan B, Ge L, Ma J, Wu Y, Guo T.

Medicine (Baltimore). 2018 Mar;97(13):e0115. doi: 10.1097/MD.0000000000010115. Review.

3.

Metastatic Renal Cell Cancer-Systemic Therapy.

Joshi A, Sahu A, Noronha V, Patil V, Prabhash K.

Indian J Surg Oncol. 2018 Mar;9(1):97-104. doi: 10.1007/s13193-018-0721-2. Epub 2018 Jan 29.

PMID:
29563746
4.

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.

Maráz A, Cserháti A, Uhercsák G, Szilágyi É, Varga Z, Révész J, Kószó R, Varga L, Kahán Z.

BMC Cancer. 2018 Mar 15;18(1):296. doi: 10.1186/s12885-018-4209-9.

5.

Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.

Yu L, Lu Y, Yao Y, Liu Y, Wang Y, Lai Q, Zhang R, Li W, Wang R, Fu Y, Tao Y, Yi S, Gou L, Chen L, Yang J.

Oncotarget. 2017 Dec 26;9(4):5197-5207. doi: 10.18632/oncotarget.23708. eCollection 2018 Jan 12.

6.

A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death.

Xie Y, Li C, Huang Y, Jia Z, Cao J.

Oncotarget. 2017 Aug 14;8(50):87209-87220. doi: 10.18632/oncotarget.20257. eCollection 2017 Oct 20.

7.

Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.

Kim YH, Bhatt L, Ahn HJ, Yang Z, Lee WK, Nam HW.

Korean J Parasitol. 2017 Oct;55(5):491-503. doi: 10.3347/kjp.2017.55.5.491. Epub 2017 Oct 31.

8.

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma.

Maroto P, Esteban E, Parra EF, Mendez-Vidal MJ, Domenech M, Pérez-Valderrama B, Calderero V, Pérez-Gracia JL, Grande E, Algaba F.

Onco Targets Ther. 2017 Sep 20;10:4635-4643. doi: 10.2147/OTT.S137677. eCollection 2017.

9.

Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer.

Du Y, Liu JQ, Tang J, Ge J, Chen Y, Cheng K, Ding J, Li ZK, Liu JY.

Oncotarget. 2017 Jul 17;8(40):68270-68279. doi: 10.18632/oncotarget.19295. eCollection 2017 Sep 15.

10.

The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

De Falco V, Carlomagno F, Li HY, Santoro M.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):307-318. doi: 10.1016/j.beem.2017.04.013. Epub 2017 May 10. Review.

PMID:
28911727
11.

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.

Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP.

Br J Clin Pharmacol. 2017 Oct;83(10):2195-2204. doi: 10.1111/bcp.13327. Epub 2017 Jul 4.

PMID:
28500677
12.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).

Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S Jr, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE.

J Thorac Oncol. 2017 May;12(5):843-849. doi: 10.1016/j.jtho.2017.01.022. Epub 2017 Feb 1.

13.

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

Buttigliero C, Bertaglia V, Novello S.

Transl Lung Cancer Res. 2016 Dec;5(6):610-627. doi: 10.21037/tlcr.2016.09.03. Review.

14.

Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world.

Kumar KA, Sadashivudu G, Krishnamani KV, Linga VG, Maddali LS, Digumarti RR.

Indian J Med Paediatr Oncol. 2016 Oct-Dec;37(4):260-264. doi: 10.4103/0971-5851.195738.

15.

Advances in antiangiogenic treatment of small-cell lung cancer.

Lu H, Jiang Z.

Onco Targets Ther. 2017 Jan 12;10:353-359. doi: 10.2147/OTT.S119714. eCollection 2017. Review.

16.

Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics.

Smaletz O, Chacón M, de Oliveira Koch L, de Carvalho Rocha DR, Cardoso FC.

Onco Targets Ther. 2016 Nov 30;9:7309-7314. eCollection 2016.

17.

Sunitinib in the treatment of metastatic renal cell carcinoma.

Schmid TA, Gore ME.

Ther Adv Urol. 2016 Dec;8(6):348-371. Epub 2016 Aug 23. Review.

18.

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.

Barrios CH, Herchenhorn D, Chacón M, Cabrera-Galeana P, Sajben P, Zhang K.

Onco Targets Ther. 2016 Sep 23;9:5839-5845. eCollection 2016.

19.

Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells.

Velma V, Dasari SR, Tchounwou PB.

Biomark Insights. 2016 Aug 24;11:113-21. doi: 10.4137/BMI.S39445. eCollection 2016.

20.

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.

Martínez-Bosch N, Guerrero PE, Moreno M, José A, Iglesias M, Munné-Collado J, Anta H, Gibert J, Orozco CA, Vinaixa J, Fillat C, Viñals F, Navarro P.

Oncotarget. 2016 Jul 26;7(30):48265-48279. doi: 10.18632/oncotarget.10199.

Supplemental Content

Support Center